Hemolytic anemia
MONDO:0003664Anemia resulting from the premature destruction of the peripheral blood red cells. It may be congenital or it may be caused by infections, medications, or malignancies.
Also known as: anaemia hemolytic, anemia hemolytic, anemia, hemolytic, hemolytic anemia
203 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New stem cell transplant trial offers hope for rare blood diseases
Disease control Recruiting nowThis study tests a stem cell transplant using blood stem cells from a half-matched family donor (haploidentical) for people with severe aplastic anemia, related MDS, or PNH. Participants receive chemotherapy and a single radiation dose before the transplant, plus a drug to preven…
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Turmeric gel could offer new hope for sickle cell patients
Disease control Recruiting nowThis early-stage trial is testing whether a skin gel made from curcumin (a compound in turmeric) can be safely absorbed by adults with stable sickle cell disease. Researchers will apply the gel to the forearms twice a week for six weeks and monitor for side effects. The goal is t…
Phase: PHASE1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New stem cell method aims to cut transplant risks
Disease control Recruiting nowThis study tests a new way to do stem cell transplants for people with severe aplastic anemia or other bone marrow failure diseases. Doctors give a smaller number of donor white blood cells along with the stem cells to try to reduce serious side effects. Up to 120 patients aged 4…
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug duo aims to rescue PNH patients failing standard care
Disease control Recruiting nowThis study tests two experimental drugs, pozelimab and cemdisiran, together in 35 adults with paroxysmal nocturnal hemoglobinuria (PNH) whose red blood cell destruction is not well-controlled by current C5 inhibitors. The goal is to see if the combination can lower hemolysis (bre…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo therapy aims to tame rare bleeding disorder
Disease control Recruiting nowThis study tests a new biologic drug called ianalumab combined with a standard platelet-boosting drug (TPO-RA) in people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The trial includes 164 adults who have tried at l…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Real-World test: can a targeted drug keep PNH in check for years?
Disease control Recruiting nowThis study follows about 200 adults with paroxysmal nocturnal hemoglobinuria (PNH) who are taking pegcetacoplan (Aspaveli/Empaveli) as part of their routine care. Researchers will track blood markers, symptoms, and side effects for up to 3 years to see how well the drug works out…
Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug danicopan under Real-World review for rare blood disorder
Disease control Recruiting nowThis study tracks 8 Korean patients with paroxysmal nocturnal hemoglobinuria (PNH) who are taking Danicopan alongside standard C5 inhibitors like eculizumab or ravulizumab. The goal is to monitor safety and check if the drug works as expected in everyday medical practice. It is a…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug pegcetacoplan tested in teens with rare blood disorder
Disease control Recruiting nowThis study tests a drug called pegcetacoplan in 12 to 17-year-olds with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The drug aims to control the disease by blocking part of the immune system. The trial will check safety, how the…
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug fabhalta under Real-World watch in korea for rare blood and kidney diseases
Disease control Recruiting nowThis study is monitoring the safety and effectiveness of the drug iptacopan (Fabhalta) in 21 Korean adults with paroxysmal nocturnal hemoglobinuria (PNH) or C3 glomerulopathy (C3G). Researchers will track side effects and lab results from routine medical records. The goal is to s…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to control rare blood disease Long-Term
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of two experimental drugs, pozelimab and cemdisiran, taken together for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. About 202 participants who completed a prior study will continue treatment to see…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for PNH patients with stubborn anemia
Disease control Recruiting nowThis study tests an experimental drug called ALN-CFB in people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cells despite standard treatment. The goal is to see if adding ALN-CFB is safe and can improve anemia. About 24 participants will receive eit…
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to control rare blood disorders without lifelong steroids
Disease control Recruiting nowThis study tests a drug called tafasitamab in adults with two rare autoimmune blood disorders: immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). The goal is to see if it can safely raise blood cell counts and reduce the need for other treatments. About 5…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene-Edited immune cells take on autoimmune blood diseases
Disease control Recruiting nowThis early-stage trial tests a one-time treatment called CTX112, made from donor immune cells edited with CRISPR technology. It aims to safely control two autoimmune diseases where the body attacks its own blood cells: immune thrombocytopenia (ITP) and warm autoimmune hemolytic a…
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New siRNA drug ADX-038 enters human trials for PNH anemia
Disease control Recruiting nowThis study tests a new drug called ADX-038 in healthy volunteers and people with PNH who still have low red blood cells despite treatment. The goal is to check safety and how the drug works in the body. It is an early-stage trial with 50 participants.
Phase: PHASE1, PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill could tame rare blood disorder when other treatments fail
Disease control Recruiting nowThis study tests a daily pill called orelabrutinib for people with autoimmune hemolytic anemia (AIHA) that hasn't responded to standard treatments. AIHA is a condition where the immune system mistakenly attacks red blood cells, causing fatigue and anemia. The trial will enroll 50…
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Second dose of experimental drug may help when first fails
Disease control Recruiting nowThis study tests whether a second course of ianalumab can help adults with two rare blood disorders—immune thrombocytopenia (ITP) and warm-antibody autoimmune hemolytic anemia (wAIHA)—who previously responded to the drug but then stopped responding. About 60 participants will rec…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental mRNA CAR-T therapy targets autoimmune diseases in first human trial
Disease control Recruiting nowThis early-phase trial tests Arnovie101, an mRNA-based CAR-T therapy given directly into the bloodstream, in 5 people with lupus or autoimmune hemolytic anemia. The goal is to see if it is safe and how the body processes it. Researchers will also check if it reduces disease activ…
Phase: EARLY_PHASE1 • Sponsor: Circunited BioPharma (Shenzhen) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for PNH patients: early access to danicopan combo therapy
Disease control AVAILABLEThis program provides early access to danicopan for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have significant extravascular hemolysis (EVH) despite treatment with Soliris or Ultomiris. Participants must be 18 or older, have anemia and high reticulocyte counts, an…
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug rilzabrutinib aims to tame rare blood disorder
Disease control Recruiting nowThis study tests an oral drug called rilzabrutinib for warm autoimmune hemolytic anemia (wAIHA), a condition where the immune system attacks red blood cells. About 90 adults who have not responded well to steroids will receive either rilzabrutinib or a placebo for 24 weeks, follo…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New transplant approach aims to tame bone marrow failure
Disease control Recruiting nowThis phase 2 trial tests a bone marrow transplant using lower doses of chemotherapy and radiation to prepare the body, along with a drug called cyclophosphamide after transplant to prevent graft-versus-host disease. It enrolls 60 people with severe aplastic anemia or related bone…
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New PNH drug iptacopan tested in Real-World chinese study
Disease control Recruiting nowThis study looks at how well the drug iptacopan works for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Researchers will track changes in hemoglobin levels and other health outcomes in 80 patients across China. The goal is to see if iptacopan impro…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug IASO-782 aims to tame immune attacks on blood cells
Disease control Recruiting nowThis early-stage trial is testing a new drug called IASO-782 in 16 adults with autoimmune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA). These conditions cause the immune system to mistakenly attack blood cells. The study's main goal is to check the drug's sa…
Phase: PHASE1 • Sponsor: Shanghai IASO Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental cell therapy targets tough blood cancers and anemia
Disease control Recruiting nowThis early-phase study is testing a new cell therapy called GT801 in 28 adults with relapsed or hard-to-treat B-cell blood cancers (like leukemia and lymphoma) or autoimmune hemolytic anemia (AIHA). The therapy uses a patient's own immune cells, modified to attack CD19-positive c…
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for rare blood disorder: experimental antibody EA5 enters human testing
Disease control Recruiting nowThis early-stage trial tests the safety of a new drug called EA5 in 24 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The drug is an antibody designed to block part of the immune system that attacks blood cells. The goa…
Phase: PHASE1 • Sponsor: Shanghai Lanyi Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could an Iron-Removing pill protect the brain after a burst aneurysm?
Disease control Recruiting nowThis study tests whether the drug deferiprone can safely lower iron levels in the brain after a bleeding aneurysm. About 66 adults who had a ruptured aneurysm will receive either deferiprone or a placebo for 14 days. Researchers will measure iron in spinal fluid, brain MRI scans,…
Phase: PHASE1, PHASE2 • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Frozen testicle tissue may help men become dads after childhood cancer
Disease control Recruiting nowThis study tests whether testicular tissue frozen before puberty can be transplanted back into adult men to restore sperm production. Five men who had fertility-threatening treatments as children will receive their own preserved tissue. The goal is to see if sperm can be found in…
Phase: NA • Sponsor: Universitair Ziekenhuis Brussel • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Hope for kids with rare blood disease: new pill under study
Disease control Recruiting nowThis study tests a medicine called iptacopan in children aged 2 to under 18 who have a rare blood disease called PNH. The goal is to see how the drug works in their bodies and if it is safe. About 12 children will take the medicine, and doctors will monitor side effects and blood…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Engineered immune cells take on tough blood disorder
Disease control Recruiting nowThis early-stage study tests a new treatment for people with a severe type of autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior therapies. The treatment uses specially engineered immune cells (CAR-T cells) from a healthy donor to target and destro…
Phase: EARLY_PHASE1 • Sponsor: The Second Hospital of Anhui Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Unlicensed cord blood units under safety spotlight in new trial
Disease control Recruiting nowThis study is checking whether unlicensed cord blood units are safe to use for stem cell transplants in children and adults with blood disorders. Researchers will closely watch for any infusion-related problems. The goal is to see if these units can be a safe option for patients …
Phase: PHASE2 • Sponsor: New York Blood Center • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for PNH patients: experimental drug HS-10542 enters human trials
Disease control Recruiting nowThis study tests a new drug called HS-10542 in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The goal is to see if the drug can safely raise hemoglobin levels and reduce the need for blood transfusions. About 50 partic…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental pill aims to ease sun sensitivity in rare blood disorder
Disease control Recruiting nowThis early-phase trial tests an oral drug called ATL-001 (ciclopirox) in 6 adults with congenital erythropoietic porphyria (CEP), a rare condition that causes severe skin damage from sunlight. The study measures whether the drug reduces skin lesions, fatigue, and other symptoms o…
Phase: PHASE1, PHASE2 • Sponsor: Atlas Molecular Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug aims to speed platelet recovery in stem cell transplant patients
Disease control Recruiting nowThis study tests whether the drug lusutrombopag can help restore platelet levels faster in patients who have had a stem cell transplant for blood disorders. About 45 adults will receive the drug after transplant, and doctors will check platelet counts at 21 days. The goal is to i…
Phase: NA • Sponsor: The General Hospital of Western Theater Command • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Desperate patients get early access to experimental drug ianalumab
Disease control AVAILABLEThis program provides early access to the drug ianalumab (VAY736) for patients with serious or life-threatening conditions like immune thrombocytopenia or Sjögren's syndrome who have no other treatment options. It is not a clinical trial but a managed access program where doctors…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a bone drug fix a rare blood disorder?
Disease control Recruiting nowThis early study tests whether zoledronic acid, a drug usually used for bone health, can help people with a rare inherited anemia called congenital dyserythropoietic anemia (CDA). Only 2 adults with CDA who have low hemoglobin or need regular transfusions will receive 4 doses of …
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug GL-0719 enters first human trials for rare blood disorder
Disease control Recruiting nowThis early-stage trial tests a new drug called GL-0719 in healthy volunteers and people with cold agglutinin disease, a rare condition where cold temperatures cause the immune system to destroy red blood cells. The study aims to check safety, how the drug moves through the body, …
Phase: PHASE1 • Sponsor: Gliknik Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental CAR-T therapy targets tough autoimmune blood diseases
Disease control Recruiting nowThis early-stage study tests a new treatment called RD06-05, a type of CAR-T cell therapy, in 27 adults with autoimmune blood diseases like immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), or Evans syndrome. The therapy aims to control the disease by targeting a…
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New RNA therapy aims to tame Out-of-Control immune system
Disease control Recruiting nowThis early-stage study tests a new treatment called RXIM002 for people with severe autoimmune diseases that haven't responded to standard therapies. The treatment uses a special RNA molecule to create immune cells that target and destroy faulty B cells, which are causing the dise…
Phase: EARLY_PHASE1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Personalized immune cell therapy takes on lupus and MS
Disease control Recruiting nowThis early-stage trial tests a new treatment for people with autoimmune diseases like lupus and multiple sclerosis that haven't responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and destroy the faulty cells causing the d…
Phase: PHASE1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New antitoxin aims to speed kidney recovery in kids with e. coli infection
Disease control Recruiting nowThis study tests a new medicine called INM004 in 220 children with hemolytic uremic syndrome (HUS) caused by E. coli bacteria. The goal is to see if it helps the kidneys recover faster and reduces the need for dialysis. Participants are children aged 9 months to 18 years who have…
Phase: PHASE3 • Sponsor: Inmunova S.A. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo aims to boost red blood cells in kids with rare blood disorder
Disease control Recruiting nowThis phase 3 study tests whether adding danicopan to standard PNH medications (ravulizumab or eculizumab) can improve hemoglobin levels in children aged 12 to 17 with paroxysmal nocturnal hemoglobinuria who still have significant anemia from extravascular hemolysis. Six participa…
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New antibody therapy targets stubborn autoimmune blood diseases
Disease control Recruiting nowThis study tests an experimental drug called CM336 in people with relapsed or refractory autoimmune cytopenia, including ITP and autoimmune hemolytic anemia. CM336 is a bispecific antibody designed to target and eliminate certain immune cells. The trial will enroll 158 adults to …
Phase: PHASE1, PHASE2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New hope for rare blood and kidney diseases: iptacopan access program opens
Disease control AVAILABLEThis program provides early access to the drug iptacopan for people with serious or life-threatening C3 glomerulopathy (C3G) or paroxysmal nocturnal hemoglobinuria (PNH) who have no other treatment options. It is designed for patients who cannot join a clinical trial or have exha…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Could potato starch and an iron drug make stem cell transplants safer?
Disease control Recruiting nowThis study is for adults with blood disorders who are getting a stem cell transplant from a matched donor. Researchers want to see if giving a special potato starch along with a drug that lowers iron (deferasirox) can help prevent serious complications like graft-versus-host dise…
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug OM336 aims to tame overactive immune system
Disease control Recruiting nowThis early-phase trial tests a new drug called OM336 in 32 adults with autoimmune cytopenias, conditions where the immune system attacks blood cells. The study focuses on safety and how the drug moves through the body, not yet on curing the disease. Participants must have tried a…
Phase: PHASE1 • Sponsor: Ouro Medicines • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New 'Smart' immune therapy takes on lupus and arthritis
Disease control Recruiting nowThis early-phase study is testing a new drug called CC312 in 18 adults with severe autoimmune diseases like lupus and rheumatoid arthritis that haven't improved with standard treatments. CC312 is a type of immune therapy designed to target and destroy faulty B cells, similar to C…
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Jun 26, 2026 18:43 UTC
-
Blood thinner breakthrough could stop clots in rare anemia
Prevention Recruiting nowThis study tests whether taking blood thinners for 12 weeks can prevent dangerous blood clots in people with autoimmune hemolytic anemia (AIHA), a rare disease where the immune system destroys red blood cells. About 72 adults with newly diagnosed or relapsed AIHA will receive eit…
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Prevention
Last updated Jun 27, 2026 08:06 UTC
-
New anemia drug enters early human testing
Symptom relief Recruiting nowThis early-stage study tests a new drug called APG-5918 in healthy volunteers and people with anemia (low red blood cells). The main goal is to check safety and how the body handles the drug, while also seeing if it can raise hemoglobin levels. About 105 participants will take pa…
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Could carbon monoxide be a medicine? new trial for sickle cell
Symptom relief Recruiting nowThis study tests a new liquid drug called HBI-002, which contains carbon monoxide, in 9 people with sickle cell disease aged 14 to 55. Participants take the drug daily for 14 days to see if it is safe and helps with symptoms. The goal is to find a better way to manage this painfu…
Phase: PHASE1, PHASE2 • Sponsor: Hillhurst Biopharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Blood cell harvest could fuel future immune disease cures
Knowledge-focused Recruiting nowThis study collects blood stem cells and immune cells from healthy volunteers and patients with primary immune deficiencies or blood disorders. The cells are used in the lab to develop new gene and cell therapies. Up to 850 adults aged 18-70 will participate. The goal is to advan…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
NIH launches massive sample collection to unlock disease secrets
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New drug iptacopan tested in Real-Life PNH patients
Knowledge-focused Recruiting nowThis study looks at how well the drug iptacopan works for people with paroxysmal nocturnal hemoglobinuria (PNH) in everyday medical practice. Researchers will track 50 Italian patients for 12 months to see if their anemia improves and if they need fewer blood transfusions. The go…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New study aims to spot lung trouble before it starts in transplant patients
Knowledge-focused Recruiting nowThis study looks for better ways to detect lung inflammation and infections early in people who have received a stem cell transplant from a donor. About 40 participants aged 5 to 70 will get regular lung scans, breathing tests, blood draws, and a procedure where a tube collects f…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study aims to unlock genetic secrets of red blood cell diseases
Knowledge-focused Recruiting nowThis research study is looking at people with inherited red blood cell disorders, such as hemolytic anemia, to better understand the genetic causes. Researchers will study blood samples from up to 400 participants to identify specific gene changes. The goal is to improve diagnosi…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Massive new registry aims to unlock secrets of rare blood disorder
Knowledge-focused Recruiting nowThis study is a registry for people with Congenital Dyserythropoietic Anemia (CDA), a rare blood disorder. Researchers will collect medical information and blood or bone marrow samples over many years to better understand how the disease progresses, its causes, and how it affects…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Thousands join fight against blindness by sharing their stories
Knowledge-focused Recruiting nowThis registry collects information from people with inherited retinal diseases, like retinitis pigmentosa and Stargardt disease. Participants share their symptoms, family history, and genetic test results online. The goal is to help researchers understand these rare diseases and …
Sponsor: Foundation Fighting Blindness • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Scientists launch Largest-Ever porphyria watch: 1,500 patients tracked for clues
Knowledge-focused Recruiting nowThis study follows 1,500 people with porphyria over many years to learn how the disease progresses, what symptoms appear, and how it affects pregnancy and lifespan. Researchers will collect medical records and lab results to create a clearer picture of the condition. No new treat…
Sponsor: The American Porphyrias Expert Collaborative • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Brain scans reveal hidden thinking problems in anemia patients
Knowledge-focused Recruiting nowThis study uses a non-invasive brain imaging technique called fNIRS to see how anemia affects thinking and memory. Researchers will measure brain activity in 323 adults with different types of anemia and compare it to cognitive test scores. The goal is to identify which brain reg…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Massive blood disorder registry aims to transform care
Knowledge-focused Recruiting nowThis study is a large registry that collects health information from up to 200,000 people with blood disorders such as hemophilia, thrombosis, and sickle cell disease. Participants are seen at Hemophilia Treatment Centers across the U.S. The goal is to gather real-world data to h…
Sponsor: American Thrombosis and Hemostasis Network • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New study tracks safety of ultomiris in pregnant women
Knowledge-focused Recruiting nowThis study follows 75 pregnant women who have taken Ultomiris (ravulizumab) for conditions like PNH or aHUS. Researchers will track pregnancy outcomes and baby health up to one year after birth. The goal is to gather safety information, not to test a new treatment.
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New pill CMS-D017 enters first human safety trials
Knowledge-focused Recruiting nowThis early-stage study tests a new drug called CMS-D017 in 88 healthy adults to see if it is safe and how the body processes it. The drug is being developed for two rare conditions: paroxysmal nocturnal hemoglobinuria (a blood disorder) and complement-mediated kidney disease. Par…
Phase: PHASE1 • Sponsor: Shenzhen Kangzhe Biotechnology Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Scientists seek immune system clues from cancer patients and healthy volunteers
Knowledge-focused Recruiting nowThis research study collects blood, bone marrow, and tissue samples from people with cancer, blood disorders, and healthy volunteers. The goal is to study how the immune system changes during different treatments, including immunotherapy and chemotherapy. By comparing samples fro…
Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Gut bacteria may hold key to better transplant outcomes
Knowledge-focused Recruiting nowThis study looks at how gut bacteria and the immune system interact in children and adults receiving stem cell transplants or CAR-T therapy. Researchers will collect stool and blood samples over time to find patterns linked to complications like infections or graft-versus-host di…
Phase: NA • Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Hospital tests if its own anemia rules actually get followed
Knowledge-focused Recruiting nowThis study looks at whether doctors at Siriraj Hospital follow a new guideline for treating anemia in patients before major surgery. Anemia is common in surgical patients and can lead to more blood transfusions and worse outcomes. The researchers will track 93 anemic patients to …
Sponsor: Siriraj Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
X-rays may damage red blood cells: study seeks safe limits
Knowledge-focused Recruiting nowThis study looks at how X-ray irradiation used during cancer surgery affects red blood cells. Researchers will take blood from 20 patients having tumor surgery and test it with different X-ray doses. They will check for changes in cell shape, flexibility, and oxygen-carrying abil…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Thousands with blood diseases to be tracked in massive chinese registry
Knowledge-focused Recruiting nowThis study is creating a large database of people in China with various blood diseases, such as leukemia, multiple myeloma, and hemophilia. Researchers will collect information from medical records and follow participants over time to learn about disease patterns, treatments, and…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Can cancer survivors still have kids? new study tracks fertility after treatment
Knowledge-focused Recruiting nowThis study follows 102 women who had fertility preservation before cancer treatment to see what happens long-term. Researchers want to know if they get pregnant naturally, use stored eggs or tissue, or decide not to have children. The goal is to improve support and care for femal…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Massive study to track Real-World safety of new blood disorder drugs
Knowledge-focused Recruiting nowThis study is collecting long-term safety and effectiveness data on treatments for various blood disorders, including hemophilia, sickle cell disease, and clotting disorders. It aims to enroll 3000 people of any age with these conditions. Researchers will monitor side effects, co…
Sponsor: American Thrombosis and Hemostasis Network • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Scientists launch Largest-Ever study of Ultra-Rare GSDs
Knowledge-focused Recruiting nowThis study tracks 200 people with ultra-rare glycogen storage diseases (GSDs) like types 0a, 0b, VII, X, XII, XIII, XV, PRKAG2 syndrome, and Danon disease. Researchers will collect medical records and other data to see how these conditions progress over time. No treatments or dru…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Blood biobank launches to fuel future research
Knowledge-focused Recruiting nowThis study is creating a collection of blood samples from 2,000 people with various blood disorders. The samples will be stored and used for future research approved by an ethics board. No treatments or drugs are being tested, and participants continue their normal care.
Sponsor: Albert Einstein College of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
New french registry tracks rare blood disorders to improve care
Knowledge-focused Recruiting nowThis study is a national registry in France that collects information on adults newly diagnosed with immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA). It aims to describe how these diseases progress and how well treatments work in real life. Researchers will tr…
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Scientists track rare gene mutation to predict blood cancer in families
Knowledge-focused Recruiting nowThis study looks at families who carry a change in the DDX41 gene, which may raise the risk of blood cancers like leukemia. Researchers will collect health questionnaires and saliva samples from up to 910 people to track who develops blood problems and when. The goal is to better…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Anemia type may predict surgery danger
Knowledge-focused Recruiting nowThis study is observing 1000 adults having moderate- to high-risk surgery to see if the type and severity of anemia they have before surgery affects their risk of complications like heart injury, kidney injury, or stroke. Researchers will compare patients with iron-deficiency ane…
Sponsor: Peking Union Medical College Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Swim faster: scientists test Warm-Up hacks for young athletes
Knowledge-focused Recruiting nowThis study looks at how different warm-up exercises affect the performance of young competitive swimmers. Fifteen athletes will try three different warm-up routines, and researchers will measure their jump height and swim times for 25, 50, and 100 meters. The goal is to find the …
Phase: NA • Sponsor: University of Palermo • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Bone needle could save lives when veins collapse in blood disease emergencies
Knowledge-focused Recruiting nowThis study looks at using a needle placed into the bone marrow (intraosseous infusion) to give fluids and medicines quickly to critically ill patients with blood diseases. Researchers will enroll 52 adults aged 18-65 to see how often the first attempt works and how safe it is. Th…
Sponsor: Shanxi Bethune Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
New study aims to personalize care for rare blood disorders
Knowledge-focused Recruiting nowThis study is for people with sickle cell disease or other rare anemias. Researchers want to use advanced genetic and blood tests to better understand each person's condition. The goal is to make diagnosis more precise so that treatments can be tailored to each patient. About 200…
Sponsor: Hospital Universitari Vall d'Hebron Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
High-Altitude stem cell transplant registry launches in tibet
Knowledge-focused Recruiting nowThis study is a registry that tracks patients with blood diseases who receive stem cell transplants at a hospital on the Qinghai-Tibet Plateau. Researchers will collect information on recovery, complications, and costs over time. The goal is to understand how high altitude affect…
Sponsor: Yigeng Cao,MD,PhD • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Simple ultrasound may reveal hidden muscle loss after cancer
Knowledge-focused Recruiting nowThis study looks at whether a quick ultrasound of the thigh muscle can detect muscle loss (sarcopenia) in people who have finished cancer treatment. Researchers will compare the ultrasound results with a standard whole-body scan (DEXA) in 55 adults aged 18-74 with certain cancers…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:31 UTC
-
Scientists probe Spleen's secrets to unlock blood disease mysteries
Knowledge-focused Recruiting nowThis study aims to better understand how the spleen filters and responds to abnormal blood cells in various diseases. Researchers will collect spleen tissue and blood from 100 adults undergoing planned splenectomy. By perfusing the spleen in the lab, they hope to uncover its role…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:56 UTC
-
New study aims to crack the code of autoimmune diseases
Knowledge-focused Recruiting nowThis study is collecting blood, urine, and stool samples from 500 children with autoimmune diseases and healthy controls. Researchers will analyze these samples to find molecular patterns that could help diagnose these conditions and guide treatment decisions. The goal is to crea…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:28 UTC
-
Scientists launch major study to unravel mysterious metabolism disorders
Knowledge-focused Recruiting nowThis study aims to learn more about rare disorders that affect how the body processes chemicals called pyrimidines and purines. These disorders can cause problems in the brain, blood, kidneys, and immune system, ranging from mild to life-threatening. Researchers will compare test…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:34 UTC
-
Liver function may affect how PNH drug works
Knowledge-focused Recruiting nowThis early-stage study is testing a single dose of the drug HSK39297 in 24 adults with paroxysmal nocturnal hemoglobinuria (PNH) who have mild or moderate liver impairment, compared to those with normal liver function. The goal is to see how the liver affects drug levels and safe…
Phase: PHASE1 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:21 UTC